Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan PK in Healthy Japanese and Caucasian Subjects
NCT03579940Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) at Day 20. Started Jun 2018; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03579940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03579940.